Form 4: Astera Labs CEO Sells Over 14,000 Shares Under Pre-Arranged Trading Plan

Astera Labs, Inc. CEO and Director Jitendra Mohan reported the sale of 14,200 shares of common stock for approximately $1.42 million, executed automatically under a Rule 10b5-1 trading plan.

Summary

• Jitendra Mohan, Chief Executive Officer and Director of Astera Labs, Inc. (ALAB), reported the sale of 14,200 shares of the company's common stock.
• The transactions occurred on May 29, 2025, at a weighted average price of $100.0003 per share, with prices ranging from $100.0000 to $100.0400.
• The total value of the shares sold amounts to approximately $1,420,004.26.
• These sales were executed automatically pursuant to a Rule 10b5-1 trading plan adopted by Mr. Mohan on December 2, 2024.
• Following these transactions, Mr. Mohan directly holds 2,262,318 shares of common stock.
• Additionally, Mr. Mohan indirectly holds 7,812,553 shares through various trusts (Living Trust, Trust, 2021 Trust 1, 2021 Trust 2, 2022 Trust 1, and 2022 Trust 2), disclaiming beneficial ownership except for his pecuniary interest.

Sentiment

Score: 5

Explanation: The transaction is a pre-planned insider sale via a 10b5-1 plan, which is a routine event for executives and does not inherently signal negative or positive company performance or outlook. It's a neutral event from an investment perspective.

Positives

• The sale was conducted under a Rule 10b5-1 trading plan, which indicates a pre-scheduled transaction rather than a reactive sale, often mitigating concerns about insider sentiment.
• The existence of a 10b5-1 plan demonstrates a commitment to compliance and transparency in insider trading activities.

Negatives

• Insider selling, even if pre-planned, can sometimes be perceived negatively by the market as it reduces the insider's direct stake in the company.

Risks

• No specific risks are mentioned in this Form 4 filing beyond the general market perception of insider selling.

Future Outlook

This Form 4 filing does not contain any forward-looking statements or guidance regarding Astera Labs' future performance or outlook.

Management Comments

• The sales reported in this Form 4 occurred automatically pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on December 2, 2024.
• The Reporting Person disclaims beneficial ownership of shares held by various trusts, except to the extent of any pecuniary interest therein, and the filing of this Form 4 is not an admission of beneficial ownership for Section 16 purposes or any other purpose.

Industry Context

Insider stock sales, particularly those executed under Rule 10b5-1 plans, are a common occurrence across all industries, including the semiconductor and connectivity sectors where Astera Labs operates. These plans allow executives to diversify their personal holdings and manage liquidity in a pre-arranged, compliant manner.

Comparison to Industry Standards

• The use of a Rule 10b5-1 trading plan for insider stock sales is a standard corporate governance practice, widely adopted by executives in publicly traded companies across global markets to mitigate concerns about trading on material non-public information.
• The reported sale volume, while significant in absolute terms, represents a small fraction of the CEO's total beneficial ownership (direct and indirect), which is common for executives managing their personal portfolios.

Stakeholder Impact

• Shareholders may observe the reduction in the CEO's direct holdings, but the pre-planned nature of the sale via a 10b5-1 plan typically lessens any negative interpretation.
• No direct impact on employees, customers, suppliers, or creditors is indicated by this filing.

Next Steps

• No specific future actions or milestones for the company are mentioned in this Form 4 filing.

Key Dates

Recommendation

Keywords

Astera Labs, ALAB, Jitendra Mohan, Insider Trading, Form 4, Stock Sale, 10b5-1 Plan, Common Stock, Semiconductor, Connectivity